HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications
Authors:
- Jaclyn F. HechtmanJHJaclyn F. Hechtman
- Alexandros D. PolydoridesAPAlexandros D. Polydorides
- 1 June 2012
- journal article
- review article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 136 (6) , 691-697
Abstract
Amplification of the human epidermal growth factor receptor 2/neu ( HER2/neu ) gene and overexpression of the HER2 protein (HER2) have been shown to occur in gastric and gastroesophageal junction adenocarcinoma in a number of studies. With a dismal survival rate, patients with these cancers stand to benefit from the identification of possible molecular targets such as HER2 for both prognostic and therapeutic purposes. Although these and other carcinomas that overexpress HER2 may have a poorer prognosis and exhibit resistance to conventional chemotherapy, they have also recently been shown to respond to targeted therapy with the anti-HER2 antibody trastuzumab. Here, we briefly review the molecular biology, histopathology, diagnostic techniques, and interpretation, as well as the clinical implications, of HER2 amplification/overexpression in gastric and gastroesophageal adenocarcinoma.Keywords
This publication has 27 references indexed in Scilit:
- Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?Virchows Archiv, 2011
- HER2 status in gastro‐oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)Histopathology, 2011
- A study of HER2 gene amplification and protein expression in gastric cancerJournal of Clinical Pathology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 2010
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patientsBritish Journal of Cancer, 2009
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomasJournal of Clinical Pathology, 2006
- Prognostic Value of Laurén Classification and c-erbB-2 Oncogene Overexpression in Adenocarcinoma of the Esophagus and Gastroesophageal JunctionAnnals of Surgical Oncology, 1999